Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration

@article{Davit2009ComparingGA,
  title={Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration},
  author={B. Davit and Patrick E. Nwakama and Gary Buehler and D. Conner and Sam H. Haidar and Devvrat T. Patel and Y. Yang and L. Yu and J. Woodcock},
  journal={Annals of Pharmacotherapy},
  year={2009},
  volume={43},
  pages={1583 - 1597}
}
  • B. Davit, Patrick E. Nwakama, +6 authors J. Woodcock
  • Published 2009
  • Medicine
  • Annals of Pharmacotherapy
  • Background: In the US, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the generic formulation provides the same rate and extent of absorption as (ie, is bioequivalent to) the innovator drug product. Thus, most orally administered generic drug products in the US are approved based on results of one or more clinical bioequivalence studies. Objective: To evaluate how well the bioequivalence measures of generic drugs approved in the US over a 12… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Safety and efficacy of generic drugs with respect to brand formulation
    • 27
    • PDF

    References

    Publications referenced by this paper.